Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs)\r\nCrohnâ��s disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase\r\nknowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently\r\nused IBD drugs and IBD drug candidates, that is, anti-TNF-a, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-a4�Ÿ7 integrin,\r\nenrofloxacin/metronidazole, and cyclosporine.We found that anti-TNF-a, antibiotics, anti-IL-12p40, anti-a4�Ÿ7 integrin, CTLA4-\r\nIg, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies,\r\nantibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the\r\nadoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding\r\nthat some well-established IBD therapeutics do not have any effect in the model highlights important differences between the\r\nexperimental model and the human disease.
Loading....